시장보고서
상품코드
1429441

세계 G-CSF(과립구 집락자극인자) 시장 보고서(2024년)

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

G-CSF(과립구 집락자극인자) 시장 규모는 향후 수년간 꾸준히 성장할 것으로 예상됩니다. 2028년 복합 연간 성장률(CAGR) 4.6%를 나타낼 전망이며 109억 8,000만 달러로 성장할 것으로 예상됩니다. 예측기간에서 예상되는 성장은 암 유병률 증가, G-CSF의 예방 수요 증가, 헬스케어비 상승, 신흥국 잠재력 높이, 기술 진보 및 바이오시밀러 의약품의 보급. 예측기간 중에 예상되는 주목할만한 동향에는 효과적이고 혁신적인 의약품의 창출을 촉진하기 위한 연구개발활동에 많은 투자, 고객기반과 지리적 시장을 확대하기 위한 합병 인수의 성장 전략에 대한 초점, 대기업과의 전략적 파트너십 구축 등이 포함됩니다. 각 기업은 신약 개발을 위한 R&D 활동을 확대하고 수익과 제품 제공을 강화하기 위해 호중구 감소증 치료를 위한 바이오시밀러 생산을 위한 공동 노력을 확대합니다.

G-CSF(과립구 집락자극인자) 시장의 성장은 암의 유병률 증가에 크게 영향을 받습니다. 암은 세계 사망 원인의 2위에 랭크되고 있어, 세계에서 약 6명에 1명의 사망을 차지하고 있습니다. 예를 들어 2023년 1월 미국 암 협회의 데이터에 따르면(2023년)에는 미국에서 새롭게 암 증례가 1,958,310명, 암 관련 사망자 수가 609,820명으로 예측되고 있습니다. 성장 인자의 범주인 G-CSF는 중요한 역할을 합니다. 골수 내에서 백혈구를 생성하는 역할을 하여 감염과 패혈증의 위험을 줄입니다. 암 환자에서 G-CSF는 회복을 촉진하고 암 화학 요법 후 호중구 감소증과 관련된 사망률을 감소시키는 데 도움이 됩니다. 또한 특정 암 치료 후 감염을 줄일 수 있습니다. 따라서 암 유병률 증가는 G-CSF 시장 확대의 원동력이 될 전망입니다.

예상되는 건강 관리 증가는 G-CSF 시장의 미래 성장에 대한 촉매 역할을 할 것으로 예상됩니다. 헬스케어 지출에는 의료기기, 의약품, 병원 케어, 의사 서비스, 공중보건 활동 등 다양한 헬스케어 요소에 대한 재정 지출이 포함됩니다. 건강 관리 지출 수준은 G-CSF 시장에 중대한 영향을 미치며 G-CSF 제품과 관련된 비용 효과, 도입률, 비용 절감, 시장 성장, 예산 고려 사항 등 측면에 영향을 미칩니다. 메디케어 메디케이드 서비스 센터의 2021년부터 2030년까지 국민 의료 지출(NHE) 보고서에서 입증된 바와 같이, 연간 국민 의료 지출은 2021년에서 2030년 사이 평균 5.1% 증가하여 2030년까지 추정 6조 8,000억 달러에 달할 것으로 예측되고 있습니다. 또한 메디케어 지출은 연간 7.2%로 증가할 것으로 예상되며 메디케이드 지출은 동기간 연간 5.6%로 증가할 것으로 예측됩니다. 그 결과, 헬스케어 지출 증가는 G-CSF 시장 성장의 주요 원동력으로 부상하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고 인플레이션이 시장에 미치는 영향
  • 우크라이나,러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계 시장 규모 실적과 성장(2018년-2023년)
  • 세계 시장 규모 예측과 성장(2023년-2028년, 2033년)

제6장 시장 세분화

  • 세계 G-CSF(과립구 집락자극인자) 시장, 유형별 세분화, 분석 및 예측(2018-2023년, 2023-2028년, 2033년)
  • 페그필 글라스팀
  • 레노그라스팀
  • 필글라스팀
  • 기타 유형
  • 세계 G-CSF(과립구 집락자극인자) 시장 : 제품별 세분화, 분석 및 예측(2018-2023년, 2023-2028년, 2033년)
  • 정제
  • 캡슐
  • 기타 제품
  • 세계 G-CSF(과립구 집락자극인자) 시장 : 용도별 세분화, 분석 및 예측(2018-2023년, 2023-2028년, 2033년)
  • 종양성 질환
  • 혈액 질환
  • 만성 및자가면역질환
  • 기타 용도

제7장 지역 및 국가 분석

  • 세계 G-CSF(과립구 집락자극인자) 시장 : 지역별, 분석 및 예측(2018-2023년, 2023-2028년, 2033년)
  • 세계 G-CSF(과립구 집락자극인자) 시장 : 국가별, 분석 및 예측(2018-2023년, 2023-2028년, 2033년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • G-CSF(과립구 집락자극인자) 시장 경쟁 구도
  • G-CSF(과립구 집락자극인자) 시장 기업 프로파일
    • Amgen Inc.
    • Coherus Biosciences Inc.
    • Sandoz
    • Biocon/Mylan
    • Teva Pharmaceuticals Inc.

제31장 기타 선도적이고 혁신적인 기업

  • Chugai Pharma
  • Intalfarmaco Group
  • Pfizer
  • Sun Pharmaceutical Industries Limited
  • BeyondSpring Inc.
  • Kyowa Hakko Kirin Co. Ltd
  • BioCad
  • Stada Arzneimittel
  • Dong-A Socio Group
  • Dr. Reddy's Laboratories
  • Celltrion Inc.
  • Emcure Pharmaceuticals
  • Accord Healthcare UK
  • Intas Pharmaceuticals
  • Spectrum Pharmaceuticals

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 미래 전망과 가능성 분석

제36장 부록

BJH 24.03.21

The G-CSF (granulocyte colony-stimulating factors) market comprises a category of colony-stimulating factors that enhance the bone marrow's capacity to generate more white blood cells. G-CSF is utilized in the treatment of patients with specific tumors, neutropenia resulting from certain chemotherapy types, or severe persistent neutropenia unrelated to cancer treatment. It is also known by other names such as Filgrastim and Granulocyte Colony-Stimulating Factor.

Key types within the G-CSF market include lenograstim, filgrastim, Pegfilgrastim, and others. Lenograstim is a glycosylated recombinant therapeutic drug that closely resembles or is identical to a naturally occurring human granulocyte colony-stimulating factor (G-CSF). The various products are available in forms such as tablets, capsules, and others, and find applications in treating oncological diseases, blood disorders, growth hormone deficiencies, chronic and autoimmune disorders, among others.

The G-CSF (Granulocyte Colony Stimulating Factors) market research report is one of a series of new reports from The Business Research Company that provides G-CSF (Granulocyte Colony Stimulating Factors) market statistics, including G-CSF (Granulocyte Colony Stimulating Factors) industry global market sizes, regional shares, competitors with a G-CSF (Granulocyte Colony Stimulating Factors) market share, detailed G-CSF (Granulocyte Colony Stimulating Factors) market segments, market trends and opportunities, and any further data you may need to thrive in the G-CSF (Granulocyte Colony Stimulating Factors) industry. This G-CSF (granulocyte colony stimulating factors) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The g-csf (granulocyte colony stimulating factors) market size has grown steadily in recent years. It will grow from $8.84 billion in 2023 to $9.17 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth observed in the historical period can be ascribed to an upsurge in cancer prevalence, robust economic expansion in emerging markets, heightened healthcare expenditure, an increase in pharmaceutical research and development expenditure, and government initiatives.

The g-csf (granulocyte colony stimulating factors) market size is expected to see steady growth in the next few years. It will grow to $10.98 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The anticipated growth in the forecast period can be attributed to the increasing prevalence of cancer, a rising demand for prophylaxis granulocyte colony-stimulating factor (G-CSF), an escalation in healthcare expenditure, the high potential of emerging economies, technological advances, and the widespread adoption of biosimilar drugs. Noteworthy trends expected in the forecast period include substantial investments in research and development activities to foster the creation of effective and innovative drugs, a heightened focus on merger and acquisition growth strategies to broaden the customer base and geographic markets, the establishment of strategic partnerships with major players to expand research and development activities for new drug developments, and a concerted effort toward biosimilar production for the treatment of neutropenia to enhance revenues and product offerings.

The growth of the G-CSF (granulocyte colony stimulating factor) market is significantly influenced by the increasing prevalence of cancer. Cancer, ranking as the second leading cause of death globally, accounts for approximately 1 in 6 deaths worldwide. For example, data from the American Cancer Society in January 2023 indicates that an estimated 1,958,310 new cancer cases and 609,820 cancer-related deaths are projected in the United States for the year 2023. G-CSF, a category of growth factors, plays a crucial role in generating white blood cells in the bone marrow, thereby reducing the risk of infection and sepsis. In cancer patients, G-CSF aids in accelerating recovery and decreasing mortality associated with neutropenia following cancer chemotherapy. Moreover, it has the potential to mitigate infections after specific cancer treatments. Consequently, the increasing prevalence of cancer is poised to be a driving force behind the expansion of the G-CSF market.

The anticipated rise in healthcare expenditure is expected to act as a catalyst for the future growth of the G-CSF market. Healthcare expenditure encompasses the financial outlay on various healthcare components, including medical equipment, pharmaceuticals, hospital care, physician services, and public health initiatives. The level of healthcare expenditure holds significant implications for the G-CSF market, influencing aspects such as cost-effectiveness, adoption rates, cost savings, market growth, and budgetary considerations related to G-CSF products. As evidenced by the 2021-2030 National Health Expenditure (NHE) report from the Centers for Medicare & Medicaid Services, annual national health spending is projected to witness an average increase of 5.1% between 2021 and 2030, reaching an estimated $6.8 trillion by 2030. Furthermore, Medicare expenditures are anticipated to grow at a 7.2% annual rate, and Medicaid spending is projected to increase at a 5.6% annual rate during the same period. Consequently, the upswing in healthcare expenditure emerges as a key driver for the growth of the G-CSF market.

Companies in the G-CSF (granulocyte colony stimulating factor) market are strategically emphasizing collaborations to foster innovation and expand their market share. The trend of partnerships, in-licensing, and out-licensing deals has been on the rise, with companies engaging in collaborative ventures with each other, as well as with academic and research institutions. A notable instance from 2022 involves Evive Biotech, a Singapore-based biopharmaceutical company, joining forces with the German pharmaceutical company APOGEPHA. The exclusive long-term license agreement was established for the commercialization of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627, a novel dimeric G-CSF long-acting fusion protein without pegylation, holds promise as a significant product in the market.

Major players in the G-CSF market are actively integrating automation into their product offerings, particularly in the form of automated injection devices, to gain a competitive advantage. Automated injection devices are medical devices designed to deliver a dose of G-CSF automatically into the body at a predetermined time post-chemotherapy. A case in point is Kyowa Kirin Co. Ltd., a Japanese pharmaceutical company, which introduced G-Lasta Subcutaneous Injection 3.6 mg BodyPod in December 2022. This long-acting G-CSF preparation aims to reduce the incidence of febrile neutropenia in patients undergoing cancer chemotherapy. The automated injection device administers a G-Lasta dose approximately 27 hours after connection, eliminating the need for an additional outpatient visit the following day for G-Lasta administration.

In December 2021, when Novartis AG, a Swiss pharmaceutical company, acquired Gyroscope Therapeutics Holdings plc for $800 million. This strategic move is expected to enhance Novartis's portfolio by incorporating G-CSF drugs, bolster gene therapy research capabilities, and bring innovative ophthalmic solutions to treat and prevent blindness on a global scale. Gyroscope Therapeutics Holdings PLC, a UK-based clinical-stage biopharmaceutical company, specializes in the research and development of biosimilars for the treatment of eye-related diseases.

Major companies operating in the g-csf (granulocyte colony stimulating factors) market report are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd., BioCad, Stada Arzneimittel, Dong-A Socio Group, Dr. Reddy's Laboratories, Celltrion Inc., Emcure Pharmaceuticals, Accord Healthcare UK, Intas Pharmaceuticals, Spectrum Pharmaceuticals, Apobiologix, Apotex Inc., Eurofarma Laboratorios, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline PLC, AstraZeneca, Merck Sharp & Dohme Corp., Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Cipla.

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2023. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the g-csf (granulocyte colony stimulating factors) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The G-CSF (granulocyte colony stimulating factors) market consists of sales of releuko, accofil, and pegylated. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on g-csf (granulocyte colony stimulating factors) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for g-csf (granulocyte colony stimulating factors)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The g-csf (granulocyte colony stimulating factors) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Pegfilgrastim; Lenograstim; Filgrastim; Other Types
  • 2) By Product: Tablet; Capsule; Other Products
  • 3) By Application: Oncological Diseases; Blood Disorders; Chronic And Autoimmune Disorders; Other Applications
  • Companies Mentioned: Amgen Inc.; Coherus Biosciences Inc.; Sandoz; Biocon/Mylan; Teva Pharmaceuticals Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. G-CSF (Granulocyte Colony Stimulating Factors) Market Characteristics

3. G-CSF (Granulocyte Colony Stimulating Factors) Market Trends And Strategies

4. G-CSF (Granulocyte Colony Stimulating Factors) Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Size and Growth

  • 5.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global G-CSF (Granulocyte Colony Stimulating Factors) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. G-CSF (Granulocyte Colony Stimulating Factors) Market Segmentation

  • 6.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pegfilgrastim
  • Lenograstim
  • Filgrastim
  • Other Types
  • 6.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Tablet
  • Capsule
  • Other Products
  • 6.3. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oncological Diseases
  • Blood Disorders
  • Chronic And Autoimmune Disorders
  • Other Applications

7. G-CSF (Granulocyte Colony Stimulating Factors) Market Regional And Country Analysis

  • 7.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 8.1. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 9.1. China G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 9.2. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 10.1. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 11.1. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 11.2. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 12.1. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 13.1. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 14.1. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 14.2. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 15.1. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 15.2. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 16.1. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 17.1. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 18.1. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 19.1. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 20.1. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 21.1. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 21.2. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 22.1. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 23.1. North America G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 23.2. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 24.1. USA G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 24.2. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 25.1. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 25.2. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 26.1. South America G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 26.2. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 27.1. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 28.1. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 28.2. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 29.1. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 29.2. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Landscape And Company Profiles

  • 30.1. G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Landscape
  • 30.2. G-CSF (Granulocyte Colony Stimulating Factors) Market Company Profiles
    • 30.2.1. Amgen Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Coherus Biosciences Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Sandoz
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Biocon/Mylan
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Teva Pharmaceuticals Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. G-CSF (Granulocyte Colony Stimulating Factors) Market Other Major And Innovative Companies

  • 31.1. Chugai Pharma
  • 31.2. Intalfarmaco Group
  • 31.3. Pfizer
  • 31.4. Sun Pharmaceutical Industries Limited
  • 31.5. BeyondSpring Inc.
  • 31.6. Kyowa Hakko Kirin Co. Ltd
  • 31.7. BioCad
  • 31.8. Stada Arzneimittel
  • 31.9. Dong-A Socio Group
  • 31.10. Dr. Reddy's Laboratories
  • 31.11. Celltrion Inc.
  • 31.12. Emcure Pharmaceuticals
  • 31.13. Accord Healthcare UK
  • 31.14. Intas Pharmaceuticals
  • 31.15. Spectrum Pharmaceuticals

32. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Benchmarking

33. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The G-CSF (Granulocyte Colony Stimulating Factors) Market

35. G-CSF (Granulocyte Colony Stimulating Factors) Market Future Outlook and Potential Analysis

  • 35.1 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제